Clinical utility of plasma p-tau217 in identifying abnormal brain amyloid burden in an Asian cohort with high prevalence of concomitant cerebrovascular disease

IF 13 1区医学 Q1 CLINICAL NEUROLOGY

Alzheimer's & Dementia Pub Date : 2025-01-14 DOI:10.1002/alz.14502

Joyce R. Chong, Saima Hilal, Boon Yeow Tan, Narayanaswamy Venketasubramanian, Michael Schöll, Henrik Zetterberg, Kaj Blennow, Nicholas J. Ashton, Christopher P. Chen, Mitchell K. P. Lai

引用次数: 0

Abstract

Using an Asian cohort with high prevalence of concomitant cerebrovascular disease (CeVD), we evaluated the performance of a plasma immunoassay for tau phosphorylated at threonine 217 (p-tau217) in detecting amyloid beta positivity (Aβ+) on positron emission tomography and cognitive decline, based on a three-range reference, which stratified patients into low-, intermediate-, and high-risk groups for Aβ+.

查看原文本刊更多论文

血浆p-tau217在亚洲脑血管病高发人群中识别异常脑淀粉样蛋白负荷的临床应用

我们使用亚洲伴发脑血管疾病（CeVD）高患病率的队列，基于三个范围的参考，评估了血浆免疫测定苏氨酸217磷酸化tau蛋白（p-tau217）在正电子发射断层扫描和认知能力下降中检测β淀粉样蛋白阳性（a β+）的性能，将患者分为a β+低、中、高风险组。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer's & Dementia 医学-临床神经学

CiteScore

14.50

自引率

5.00%

发文量

299

审稿时长

3 months

期刊介绍： Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.